StocksMedium•9 October 2026•
1 min read
Retension Pharmaceuticals and TRex Bio Price IPOs on Nasdaq
Key Facts
1Retension Pharmaceuticals priced its initial public offering at $12.00 per share.
2TRex Bio priced its initial public offering on the Nasdaq at $14.00 per share.
3TRex Bio expects to raise approximately $116.7 million in gross proceeds from its public offering.
Retension Pharmaceuticals priced its initial public offering at $12.00 per share. According to Investing.com, TRex Bio also priced its IPO on the Nasdaq at $14.00 per share, with the company expecting to raise approximately $116.7 million in gross proceeds from the public offering.
These listings coincide with NDAQ, the Nasdaq exchange operator, closing at $92.37 on October 8, 2026. The moves reflect ongoing activity within the pharmaceutical and biotech sectors to secure capital for operations, as NDAQ saw a session high of $92.69 and a low of $91.1 on October 8.